Isopropylamine

Isopropylamine

SCHEMBL525520

CC(C)N.CC(NCCS(=O)(=O)O)c1ccccc1.OCl

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.49
LMNA P02545 2/20 0.49
CHRM2 P08172 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
CHRM1 P11229 1/20 0.49
SMPD1 P17405 1/20 0.49
DRD1 P21728 1/20 0.49
TBXA2R P21731 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A4 P31645 1/20 0.49
ADRA1A P35348 1/20 0.49
OPRM1 P35372 1/20 0.49
DRD3 P35462 1/20 0.49
CASR P41180 1/20 0.49
HTR2B P41595 1/20 0.49
SLC6A3 Q01959 1/20 0.49
KCNH2 Q12809 1/20 0.49
CYP1A2 P05177 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30147199 0.92 CYP3A4 (0.56) CYP3A4LMNACHRM2HTR1AADRA2A
SCHEMBL10231054 0.83 CYP3A4 (0.53) CYP3A4LMNACHRM2HTR1AADRA2A
SCHEMBL14099965 0.83 CYP3A4 (0.53) CYP3A4LMNACHRM2HTR1AADRA2A
SCHEMBL10231050 0.83 CYP3A4 (0.53) CYP3A4LMNACHRM2HTR1AADRA2A
SCHEMBL10388847 0.73 MTOR (0.38) CYP3A4LMNACYP2D6CYP2C19KMT2A
SCHEMBL10779809 0.73 CYP3A4 (0.70) CYP3A4LMNACHRM2HTR1AADRA2A
SCHEMBL24406703 0.73 CYP3A4 (0.76) CYP3A4LMNACHRM2HTR1AADRA2A
SCHEMBL3881700 0.73 CYP3A4 (0.76) CYP3A4LMNACHRM2HTR1AADRA2A
SCHEMBL5471668 0.73 CYP3A4 (0.76) CYP3A4LMNACHRM2HTR1AADRA2A
SCHEMBL3881699 0.73 CYP3A4 (0.76) CYP3A4LMNACHRM2HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160206579-A1 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-07-21 US claimed
US-20160193166-A1 ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2016-07-07 US claimed
EP-2393490-A1 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2011-12-14 EP claimed
US-20110172171-A1 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2011-07-14 US claimed
EP-2326321-A1 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA Inserm (Institut National de la Santé et de la Recherche Scientifique) (FR) 2011-06-01 EP claimed
WO-2010089355-A1 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2010-08-12 WO claimed
US-20100184707-A1 ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2010-07-22 US claimed
EP-2167068-A2 ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS Inserm-Institut National De La Sante Et De La Recherche Medicale (FR) 2010-03-31 EP claimed
WO-2010029021-A1 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2010-03-18 WO claimed
EP-2163246-A1 Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2010-03-17 EP claimed
WO-2009004082-A2 ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2009-01-08 WO claimed
EP-2011491-A1 Anticonvulsive pharmaceutical compositions INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2009-01-07 EP claimed
US-11998602-B2 Methods for promoting myelination and for treating demyelinating diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2024-06-04 US disclosed
US-20230022659-A1 COMPOSITIONS AND METHODS FOR PRESERVING OR INCREASING PLATELET FUNCTION WASHINGTON UNIVERSITY 2023-01-26 US disclosed
US-20210023218-A1 METHODS FOR PROMOTING MYELINATION AND FOR TREATING DEMYELINATING DISEASES THE SCRIPPS RESEARCH INSTITUTE 2021-01-28 US disclosed
WO-2019172969-A1 METHODS FOR PROMOTING MYELINATION AND FOR TREATING DEMYELINATING DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2019-09-12 WO disclosed
WO-2010029021-A1 TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2010-03-18 WO disclosed
EP-2163246-A1 Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2010-03-17 EP disclosed
WO-2009004082-A2 ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2009-01-08 WO disclosed
EP-2011491-A1 Anticonvulsive pharmaceutical compositions INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2009-01-07 EP disclosed